Progress and problems with the use of viral vectors for gene therapy
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Gene therapy has a history of controversy. Encouraging results are starting to emerge from the clinic, but questions are still being asked about the safety of this new molecular medicine. With the development of a leukaemia-like syndrome in two of the small number of patients that have been cured of a disease by gene therapy, it is timely to contemplate how far this technology has come, and how far it still has to go.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In all cases of leukemia, the SCID X-1 correcting gene had inserted into the patient genome within or near tumor-promoting genes and caused transcriptional activation (Check, 2002; Kaiser, 2003; Thomas et al., 2003).”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Thomas et al., 2003
Citations
Cites
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundA serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundHIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“AAV vector genomes flanked by AAV2 inverted terminal repeats (ITRs) have also been successfully cross-packaged in the capsids of alternative serotypes, creating a portfolio of pseudotypes with different specificitie”
BackgroundRubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L., Kopinja, J., Rooney, D. L., Zhang, M., Ihrig, M. M., McManus, M. T., et al. (2003) · Nature Genetics · doi:10.1038/ng1117 · Cited by 1,501
Naldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499 · cited 1×
“They have proven to be effective tools for gene delivery to the central nervous system (CNS), generating long-term gene expression in the absence of inflammatio”
BackgroundViral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Kay, M. A., Glorioso, J. C., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,342
Self-citationKordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251 · cited 1×
“gov/htbin-post/Omim/dispmim?168600">Parkinson disease”
Cited by
Items 501–600 of 1,002
Das, J., Han, J. W., Choi, Y., Song, H., Cho, S., Park, C., Seo, H. G., & Kim, J. (2016) · Scientific Reports · doi:10.1038/srep29197 · Cited by 68
Nuclear-targeted siRNA delivery for long-term gene silencing
Li, N., Yang, H., Yu, Z., Li, Y., Pan, W., Wang, H., & Tang, B. (2017) · Chemical Science · doi:10.1039/c6sc04293g · Cited by 60
Kolte, A., Patil, S., Lesimple, P., Hanrahan, J. W., & Misra, A. R. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.03.094 · Cited by 68
Liquid biopsy in pancreatic cancer: the beginning of a new era
Yadav, D. K., Bai, X., Yadav, R. K., Singh, A., Li, G., Ma, T., Chen, W., & Liang, T. (2018) · Oncotarget · doi:10.18632/oncotarget.24809 · Cited by 68
“Nonetheless, whole RNA sequence can’t be bundled inside one exosome, because of its small size, which was contrasted and retrovirus particles of a comparable size that can just pack 10 kb transcriptome, subsequently, single exosome conveys just a predetermined number of transcripts [358].”
BackgroundAptamer-conjugated mesoporous silica nanoparticles for simultaneous imaging and therapy of cancer
Vandghanooni, S., Barar, J., Eskandani, M., & Omidi, Y. (2019) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2019.115759 · Cited by 68
Progress in arginine-based gene delivery systems
Zhou, Y., Han, S., Liang, Z., Meng, Z., Liu, G., & Wu, J. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00498g · Cited by 68
Gene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development
Massaro, G., Geard, A. F., Liu, W., Coombe-Tennant, O., Waddington, S. N., Baruteau, J., Gissen, P., & Rahim, A. A. (2021) · Biomolecules · doi:10.3390/biom11040611 · Cited by 68
“Adenoviruses are non-enveloped viruses with an icosahedral capsid containing a double-stranded DNA (dsDNA) genome [37].”
BackgroundInfluentialEnzymatic Synthesis of Polyesters and Their Bioapplications: Recent Advances and Perspectives
Hevilla, V., Sonseca, Á., Echeverría, C., Muñoz‐Bonilla, A., & Fernández‐García, M. (2021) · Macromolecular Bioscience · doi:10.1002/mabi.202100156 · Cited by 68
Expressing short hairpin RNAs in vivo
Snøve, O., & Rossi, J. J. (2006) · Nature Methods · doi:10.1038/nmeth927 · Cited by 68
“Researchers should be aware, however, that retroviruses are only able to access the nucleus of dividing cell”
BackgroundLipid- and polymer-based nanoparticle systems for the delivery of CRISPR/Cas9
Ashok, B., Peppas, N. A., & Wechsler, M. E. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102728 · Cited by 68
Apaolaza, P. S., del Pozo‐Rodríguez, A., Torrecilla, J., Rodríguez‐Gascón, A., Rodríguez, J. M., Friedrich, U., Weber, B. H. F., & Solinís, M. Á. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.033 · Cited by 67
“However, the clinical application of viral vectors is limited due to concerns over their immunogenicity and toxicity [12,13].”
BackgroundBioengineered nanoparticles for siRNA delivery
Kozielski, K., Tzeng, S. Y., & Green, J. J. (2013) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1233 · Cited by 67
Improved Cell-Penetrating Zinc-Finger Nuclease Proteins for Precision Genome Engineering
Liu, J., Gaj, T., Wallen, M. C., & Barbas, C. F. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.6 · Cited by 61
Locating and labeling neural stem cells in the brain
Landgren, H., & Curtis, M. A. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22319 · Cited by 67
“Viral Vectors Viral gene delivery have used in many studies of adult neurogenesis and is also extensively used in human gene therapy (Cockrell and Kafri, 2007; Thomas et al., 2003; Azzouz et al., 2004).”
BackgroundDevelopment of recombinant cationic polymers for gene therapy research
Canine, B., & Hatefi, A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.001 · Cited by 67
“In the past decade, there has been significant progress in the development of viral vectors which gives them a significant edge over the non-viral alternative [2].”
BackgroundGunkel‐Grabole, G., Sigg, S., Lomora, M., Lörcher, S. L., Palivan, C. G., & Meier, W. P. (2015) · Biomaterials Science · doi:10.1039/c4bm00230j · Cited by 67
Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis
Bhise, N. S., Shmueli, R. B., Sunshine, J. C., Tzeng, S. Y., & Green, J. J. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.558082 · Cited by 65
“Polymeric gene delivery has gained attention as an alternative to viral gene delivery, which suffers from limited cargo capacity, immune response, and the possibility of insertional mutagenesis [111].”
BackgroundWu, Q., Sharma, S., Cui, H., LeBlanc, S. E., Zhang, H., Muthuswami, R., Nickerson, J. A., & Imbalzano, A. N. (2016) · Oncotarget · doi:10.18632/oncotarget.8384 · Cited by 67
“Delivery to and continued expression of knockdown vectors in most tissues and specifically in tumors presents significant challenges [76].”
Das, J., Choi, Y., Song, H., & Kim, J. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw020 · Cited by 67
Kakeda, M., Hiratsuka, M., Nagata, K., Kuroiwa, Y., Kakitani, M., Katoh, M., Oshimura, M., & Tomizuka, K. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302483 · Cited by 67
Ohbayashi, F., Balamotis, M. A., Kishimoto, A., Aizawa, E., Diaz, A., Hasty, P., Graham, F. L., Caskey, C. T., & Mitani, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506598102 · Cited by 68
Liu, W., Xue, Y., Peng, N., He, W., Zhuo, R., & Huang, S. (2011) · Journal of Materials Chemistry · doi:10.1039/c1jm11460c · Cited by 66
piggyBac as a high-capacity transgenesis and gene-therapy vector in human cells and mice
Li, R., Zhuang, Y., Han, M., Xu, T., & Wu, X. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.010827 · Cited by 66
“A number of viral and non-viral gene delivery systems have been developed over the years (Atkinson and Chalmers, 2010; Thomas et al., 2003).”
BackgroundmiRNAs as Potential Treatment Targets and Treatment Options in Cancer
Petrović, N., & Ergün, S. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-017-0314-8 · Cited by 66
Inoue, R., Moghaddam, K. A., Ranasinghe, M., Saeki, Y., Chiocca, E. A., & Wade‐Martins, R. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302284 · Cited by 66
Coutu, D. L., Yousefi, A., & Galipeau, J. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22296 · Cited by 65
“This approach has a number of inherent limitations that include: (1) inadequate gene transfer efficiency and gene expression, (2) inefficient targeting of appropriate cells or tissues, and (3) poor overall safety profile of the vectors (fatal immune responses, insertional mutagenesis, detection of viral vectors in sem…”
BackgroundEmerging Concepts and Challenges in Rheumatoid Arthritis Gene Therapy
Deviatkin, A. A., Vakulenko, Y. A., Akhmadishina, L. V., Tarasov, V. V., Beloukhova, M. I., Zamyatnin, A. A., & Lukashev, A. N. (2020) · Biomedicines · doi:10.3390/biomedicines8010009 · Cited by 65
“It was concluded that it is necessary to profoundly understand the characteristics of each particular vector used in gene therapy before its clinical implication [123].”
BackgroundBranched Antisense and siRNA Co‐Assembled Nanoplatform for Combined Gene Silencing and Tumor Therapy
Liu, J., Lu, X., Wu, T., Wu, X., Han, L., & Ding, B. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202011174 · Cited by 65
Engineering Efficient CAR‐T Cells via Electroactive Nanoinjection
Shokouhi, A., Chen, Y., Yoh, H. Z., Brenker, J., Alan, T., Murayama, T., Suu, K., Morikawa, Y., Voelcker, N. H., & Elnathan, R. (2023) · Advanced Materials · doi:10.1002/adma.202304122 · Cited by 65
Feng, S., Xie, X., Liu, J., Li, A., Wang, Q., Guo, D., Li, S., Li, Y., Wang, Z., Guo, T., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02139-z · Cited by 65
“Despite ongoing improvements in viral vectors [74], their applications in the delivery of CRISPR/Cas system are still hindered by the issues with immunogenicity [75], mutagenesis [76], limited packaging capacity as well as scale-up manufacturing [77, 78].”
BackgroundGrognot, M., & Gallot, G. (2015) · Applied Physics Letters · doi:10.1063/1.4930168 · Cited by 65
Sengupta, A., Kelly, S. C., Dwivedi, N., Thadhani, N. N., & Prausnitz, M. R. (2014) · ACS Nano · doi:10.1021/nn500100x · Cited by 65
Tumor-targeting bacterial therapy: A potential treatment for oral cancer (Review)
LIU, S., Xu, X., Zeng, X. Y., Li, L., Chen, Q., & LI, J. (2014) · Oncology Letters · doi:10.3892/ol.2014.2525 · Cited by 65
“…adeno-associated virus, herpes simplex virus (HSV)-1, HSV amplicon, Sindbis, poliovirus replicon and lenti-virus/Moloney murine leukemia virus; and non-viral vectors, such as therapeutic DNA, microRNA, short hairpin (sh)RNA, small interfering (si)RNA and oligodeoxynucleotides (ODNs) (24-27).”
Recent advances of biomaterials in biotherapy
Li, L., He, Z., Wei, X., & Wei, Y.-Q. (2016) · Regenerative Biomaterials · doi:10.1093/rb/rbw007 · Cited by 67
“Although many viral vectors, including adenovirus, adenoassociated virus, lentivirus and retrovirus have been widely investigated in gene delivery, severe immune/inflammatory reactions, the risk of recombination with wild-type viruses, limited cargo packaging capacity and difficulty of production significantly limited…”
BackgroundWu, D., Zhang, Y., Xu, X., Guo, T., Xie, D., Zhu, R., Chen, S., Ramakrishna, S., & He, L. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.03.030 · Cited by 65
Biomineralization‐Based Virus Shell‐Engineering: Towards Neutralization Escape and Tropism Expansion
Wang, X., Deng, Y., Li, S., Wang, G., Qin, E.-D., Xu, X., Tang, R., & Qin, C. (2012) · Advanced Healthcare Materials · doi:10.1002/adhm.201200034 · Cited by 65
Engineered E. coli delivers therapeutic genes to the colonic mucosa
Castagliuolo, I., Beggiao, E., Brun, P., Barzon, L., Goussard, S., Manganelli, R., Grillot‐Courvalin, C., & Palù, G. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302493 · Cited by 65
Delivery technologies for in utero gene therapy
Palanki, R., Peranteau, W. H., & Mitchell, M. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.11.002 · Cited by 64
The Duality of OncomiR Addiction in the Maintenance and Treatment of Cancer
Cheng, C. J., & Slack, F. J. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e318258b75b · Cited by 64
“Virally delivered miRNA sponges, miRZip vectors, and tough decoy RNAs have all demonstrated success at inhibiting miRNAs; however, in a therapeutic setting, these virus-based delivery systems suffer from significant safety concerns such as possible immunogenicity and chromosomal interruptions.(73) Nonviral nanoscale s…”
BackgroundLocal delivery of small and large biomolecules in craniomaxillofacial bone
Ji, W., Wang, H., van den Beucken, J. J. J. P., Yang, F., Walboomers, X. F., Leeuwenburgh, S. C. G., & Jansen, J. A. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.03.003 · Cited by 65
Sun, Y., Liu, H., Cheng, L., Zhu, S., Cai, C., Yang, T., Yang, L., & Ding, P. (2017) · Polymer International · doi:10.1002/pi.5490 · Cited by 64
RNAi Therapeutics and Applications of MicroRNAs in Cancer Treatment
Uchino, K., Ochiya, T., & Takeshita, F. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt052 · Cited by 63
“Although viral delivery has frequently shown higher efficiency than that by non-viral systems, preliminary clinical studies have shown that it triggered strong inflammatory reactions (36), and these delivery vectors have caused the death of several patients in the clinic (37,38).”
BackgroundEvans, J. H. (2020) · doi:10.1093/oso/9780197519561.001.0001 · Cited by 63
mRNA therapies: Pioneering a new era in rare genetic disease treatment
Shen, G., Liu, J., Yang, H., Xie, N., & Yang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.056 · Cited by 63
Extracellular Vesicle‐Based mRNA Therapeutics and Vaccines
Li, Q., Xing, H., Naeem, A., Zhang, K., Zheng, A., Huang, Y., & Lu, M. (2025) · Exploration · doi:10.1002/exp.20240109 · Cited by 64
“Adeno-associated viruses (AAVs), due to their high infection efficiency, are effective but may trigger unwanted immune responses [75], and their toxicity and size limitations restrict further development [76].”
O’Mahony, A., Godinho, B. M. D. C., Cryan, J. F., & O’Driscoll, C. M. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23672 · Cited by 64
Cationic amphiphilic calixarenes to compact DNA into small nanoparticles for gene delivery
Rodik, R. V., Anthony, A.-S., Kаlchеnkо, V. I., Mély, Y., & Klymchenko, A. S. (2014) · New Journal of Chemistry · doi:10.1039/c4nj01395f · Cited by 63
Zidovska, A., Evans, H. M., Ewert, K. K., Quispe, J. D., Carragher, B. O., Potter, C. S., & Safinya, C. R. (2008) · The Journal of Physical Chemistry B · doi:10.1021/jp806863z · Cited by 63
Vlassov, A. V., Korba, B. E., Farrar, K., Mukerjee, S., Seyhan, A. A., Ilves, H., Kaspar, R. L., Leake, D., Kazakov, S. A., & Johnston, B. H. (2007) · Oligonucleotides · doi:10.1089/oli.2006.0069 · Cited by 63
“Although much progress has been made in developing gene-therapy vectors, some obstacles remain (Thomas et al., 2003).”
Gene Replacement Therapy: A Primer for the Health-system Pharmacist
Petrich, J., Marchese, D., Jenkins, C., Storey, M., & Blind, J. E. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019854962 · Cited by 63
“Viral vectors are foreign to the body, and the immune mechanisms of developing potential anti-vector antibodies or an immune response may impact both safety and efficacy outcomes for gene therapy studies.(16) Not only could anti-vector antibodies potentially inhibit transduction, thereby rendering the therapy ineffect…”
BackgroundInfluentialRapid Functional Exhaustion and Deletion of CTL following Immunization with Recombinant Adenovirus
Krebs, P., Scandella, E., Odermatt, B., & Ludewig, B. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4559 · Cited by 63
“Discussion Induction of T cell immunity with rec-AdV is considered to be an option for vaccination approaches against infectious diseases and cancer (1).”
BackgroundLeal, C., Ewert, K. K., Shirazi, R. S., Bouxsein, N. F., & Safinya, C. R. (2011) · Langmuir · doi:10.1021/la200679x · Cited by 63
Gene Therapy for the Treatment of Musculoskeletal Diseases
Evans, C. H., Ghivizzani, S. C., Herndon, J. H., & Robbins, P. D. (2005) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/00124635-200507000-00003 · Cited by 63
“After safety testing (3), in a double-blinded fashion, two of the recipients’ MCP joints 2-4 were injected with genetically modified cells, while the other two were injected with naïve control cells (4).”
BackgroundMethodMultifunctional "core-shell" nanoparticles-based gene delivery for treatment of aggressive melanoma
Li, L., Song, L., Yang, X., Li, X., Wu, Y., He, T., Wang, N., Yang, S., Zeng, Y., Yang, L., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.019 · Cited by 62
Chien, Y., Hsiao, Y.-J., Chou, S.-J., Lin, T.-Y., Yarmishyn, A. A., Lai, W.-Y., Lee, M.-S., Lin, Y.-Y., Lin, T.-W., Hwang, D.-K., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01717-x · Cited by 57
“Recent developments in nanomedicine overcome this difficulty by introducing a nontoxic delivery of CRISPR-Cas9 components that can significantly alleviate safety concerns raised by viral vectors [20].”
BackgroundStem cells to treat muscular dystrophies – Where are we?
Meng, J., Muntoni, F., & Morgan, J. E. (2010) · Neuromuscular Disorders · doi:10.1016/j.nmd.2010.10.004 · Cited by 64
“But they have the drawbacks of a relatively small gene insert size [59,60] and possible insertional mutagenesis in the host genome [61,62].”
BackgroundBöldicke, T. W. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00002.x · Cited by 62
Supramolecular Assemblies of Peptides or Nucleopeptides for Gene Delivery
Wang, H., Feng, Z., & Xu, B. (2019) · Theranostics · doi:10.7150/thno.31854 · Cited by 62
“intrinsic drawbacks, including low cargo capacity, immunogenicity, and limitation in large scale production [3-7].”
BackgroundRNA-based therapeutics for colorectal cancer: Updates and future directions
Liu, J., & Guo, B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104550 · Cited by 62
Shim, M. S., & Xia, Y. (2013) · Angewandte Chemie · doi:10.1002/ange.201209633 · Cited by 62
Dash, B. C., Thomas, D., Monaghan, M. G., Carroll, O., Chen, X., Woodhouse, K. A., O’Brien, T., & Pandit, A. S. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.06.037 · Cited by 62
Sugano, E., Isago, H., Wang, Z., Murayama, N., Tamai, M., & Tomita, H. (2010) · Gene Therapy · doi:10.1038/gt.2010.140 · Cited by 62
The development and regulation of gene repair
Liu, L., Parekh‐Olmedo, H., & Kmiec, E. B. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1156 · Cited by 62
“In a recent review of viral gene therapy, Thomas et al”
BackgroundGO: a functional reporter system to identify and enrich base editing activity
Katti, A., Foronda, M., Zimmerman, J., Diaz, B. J., Zafra, M. P., Goswami, S., & Dow, L. E. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa124 · Cited by 61
“Stable viral expression of BE enzymes drives efficient gene modification, even in the absence of selection; however, it may induce ongoing off-target effects (27), or cause immune-rejection of cells transplanted into recipient animals (28).”
BackgroundNanobiomaterial vectors for improving gene editing and gene therapy
Hu, S. W., Ding, T., Tang, H., Guo, H., Cui, W., & Shu, Y. (2023) · Materials Today · doi:10.1016/j.mattod.2023.04.011 · Cited by 61
Non-condensing polymeric nanoparticles for targeted gene and siRNA delivery
Xu, J., Ganesh, S., & Amiji, M. M. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.036 · Cited by 61
“Viral vectors usually present high efficiency for infection and have broad tropism, which make them to be the most prevailing vectors in gene therapy [3].”
BackgroundInfluentialHe, S., Fan, W., Wu, N., Zhu, J., Miao, Y., Miao, X., Li, F., Zhang, X., & Gan, Y. (2018) · Nano Letters · doi:10.1021/acs.nanolett.7b05430 · Cited by 58
Genetic Hearing Loss and Gene Therapy
Carpena, N. T., & Lee, M. Y. (2018) · Genomics & Informatics · doi:10.5808/gi.2018.16.4.e20 · Cited by 61
Non-Viral Vector-Mediated Gene Therapy for ALS: Challenges and Future Perspectives
Ediriweera, G. R., Chen, L., Yerbury, J. J., Thurecht, K. J., & Vine, K. L. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00297 · Cited by 61
Nonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy
Wang, Y., Zhang, R., Tang, L., & Li, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030512 · Cited by 61
“Viruses are efficacious in delivering mRNA into cells; however, they are not sufficiently safe because they might integrate into the host genome [20].”
BackgroundLiu, L., Liu, H., Visner, G. A., & Fletcher, B. S. (2006) · The FASEB Journal · doi:10.1096/fj.06-6254fje · Cited by 61
“tions and cellular toxicity that limit their utility (17, 18).”
BackgroundPTTG: an important target gene for ovarian cancer therapy
Panguluri, S. K., Yeakel, C., & Kakar, S. S. (2008) · Journal of Ovarian Research · doi:10.1186/1757-2215-1-6 · Cited by 60
“Although there are many other viral vectors such as retroviruses, adeno-associated viruses (AAVs), lentiviruses (LVs), and herpes simplex viruses (HSVs) used for cancer and other gene therapies, the high infectivity of most mammalian cell types, high expression level of the transgene, ease for achieving high virus tit…”
BackgroundFrom Endocytosis to Nonendocytosis: The Emerging Era of Gene Delivery
Zhou, J. J., Shao, Z., Liu, J., Duan, Q., Wang, X., Li, J., & Yang, H. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b01131 · Cited by 60
Micelleplexes as nucleic acid delivery systems for cancer-targeted therapies
Pereira‐Silva, M., Jarak, I., Alvarez‐Lorenzo, C., Concheiro, Á., Paiva‐Santos, A. C., Veiga, F., & Figueiras, A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.041 · Cited by 60
Arginine-rich polyplexes for gene delivery to neuronal cells
Morris, V. B., & Labhasetwar, V. D. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.04.052 · Cited by 60
“Although viral vectors are more effective for gene expression in neurons, in vitro and in vivo, its toxicological and immunological problems are the major issues in their clinical translation [29].”
Xin, K.-Q., Jounai, N., Someya, K., Honma, K., Mizuguchi, H., Naganawa, S., Kitamura, K., Hayakawa, T., Saha, S., Takeshita, F., et al. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302590 · Cited by 60
Park, M. H., Lee, J. K., Choi, S., Ahn, J., Jin, H. K., Park, J., & Bae, J. (2013) · Brain Research · doi:10.1016/j.brainres.2013.05.045 · Cited by 60
State-of-the-art 2003 on PKU gene therapy
Ding, Z., Harding, C. O., & Thöny, B. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.09.010 · Cited by 60
“Nonetheless, the experiments demonstrate the high potential of gene therapy using rAAV, as it has already been shown for other monogenic diseases in human trials (including for instance haemophilia B or coagulation factor IX deficiency and cystic fibrosis [26]).”
BackgroundMethodInfluentialBarker, S. E., Broderick, C. A., Robbie, S. J., Duran, Y., Natkunarajah, M., Buch, P., Balaggan, K. S., MacLaren, R. E., Bainbridge, J. W. B., Smith, A. J., et al. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1327 · Cited by 59
“It has been established previously that, although adenoviral vectors induce strong immune responses that severely inhibit the efficacy of repeated vector administration, AAV vectors are much less immunogenic [38].”
BackgroundGhițman, J., & Voicu, Ș. I. (2022) · Carbohydrate Polymer Technologies and Applications · doi:10.1016/j.carpta.2022.100266 · Cited by 59
“…classified into viral ( e. g. , retroviruses, adenoviruses, etc.) and non-viral vectors (polymeric based nanoparticles), and particularly favoring and exploiting the non-viral vectors that may overcome the shortcomings related to the use of viral vectors (Jones et al., 2013; Thomas et al., 2003).”
Optimizing cationic and neutral lipids for efficient gene delivery at high serum content
Chan, C.-L., Ewert, K. K., Majzoub, R. N., Yeu-Kuang, H., Liang, K. S., Leal, C., & Safinya, C. R. (2014) · The Journal of Gene Medicine · doi:10.1002/jgm.2762 · Cited by 59
“efficient nonviral vectors because of the safety concerns associated with engineered viruses [9-12].”
BackgroundGene delivery to the retina: focus on non-viral approaches
Naik, R. J., Mukhopadhyay, A., & Ganguli, M. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.09.012 · Cited by 59
Choi, B., Cui, Z., Kim, S., Fan, J., Wu, B. M., & Lee, M. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb00843c · Cited by 59
Thermoresponsive polymers as gene and drug delivery vectors: architecture and mechanism of action
Calejo, M. T., Sande, S. A., & Nyström, B. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.846906 · Cited by 59
“The presence of viral capsid proteins can trigger the activation of the immunological defense systems, particularly in cases where the patient has been sensitized by wildtype infections [111].”
BackgroundMaterials promoting viral gene delivery
Kaygisiz, K., & Synatschke, C. V. (2020) · Biomaterials Science · doi:10.1039/d0bm01367f · Cited by 59
Ultrasonic particles: An approach for targeted gene delivery
Walsh, A. P. G., Gordon, H. N., Peter, K., & Wang, X. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113998 · Cited by 59
“Comparing LNPs to the conventional viral vectors, the latter have been associated with carcinogenicity or immunogenicity, difficulty in production, and limitations in packaging capacity; therefore LNPs provide safer and more efficient delivery [9-15].”
Microbubble–Nanoparticle Complexes for Ultrasound-Enhanced Cargo Delivery
Chapla, R., Huynh, K. T., & Schutt, C. E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112396 · Cited by 58
Histone H3 Tail Peptides and Poly(ethylenimine) Have Synergistic Effects for Gene Delivery
Reilly, M. J., Larsen, J. D., & Sullivan, M. O. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200372s · Cited by 58
Park, H., Tsutsumi, H., & Mihara, H. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.03.049 · Cited by 58
Micro and nanotechnologies in heart valve tissue engineering
Hasan, A., Saliba, J., Modarres, H. P., Bakhaty, A. A., Nasajpour, A., Mofrad, M. R. K., & Sanati‐Nezhad, A. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.07.001 · Cited by 58
Baek, A., Baek, Y. M., Kim, H., Jun, B., & Kim, D. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00025 · Cited by 58
Stenström, P., Manzanares, D., Zhang, Y., Ceña, V., & Malkoch, M. (2018) · Molecules · doi:10.3390/molecules23082028 · Cited by 58
Lestrell, E., Patolsky, F., Voelcker, N. H., & Elnathan, R. (2019) · Materials Today · doi:10.1016/j.mattod.2019.08.012 · Cited by 58
Cystic Fibrosis: Overview of the Current Development Trends and Innovative Therapeutic Strategies
Almughem, F. A., Aldossary, A. M., Tawfik, E. A., Alomary, M. N., Alharbi, W. S., Alshahrani, M. Y., & Alshehri, A. A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070616 · Cited by 58
Viral and Transgenic Reporters and Genetic Analysis of Adult Neurogenesis
Enikolopov, G., Overstreet-Wadiche, L., & Ge, S. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018804 · Cited by 51
“Viral gene delivery has been used extensively to transduce cells in a wide range of species, including humans, as an approach to gene therapy (Thomas et al. 2003; Cockrell and Kafri 2007).”
BackgroundDelivery of nucleic acids by cell-penetrating peptides: application in modulation of gene expression
Lehto, T. (2011) · DSpace repository (University of Tartu) · Cited by 66
Alvi, M. M., Sivasankaran, S., & Singh, M. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1793990 · Cited by 57
Towards the Clinical Application of Gene Therapy for Genetic Inner Ear Diseases
Lahlou, G., Calvet, C., Giorgi, M., Lecomte, M.-J., & Safieddine, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031046 · Cited by 57
Wang, Y., Li, J., Chen, Y., & Oupický, D. (2015) · Biomaterials Science · doi:10.1039/c5bm00003c · Cited by 57
Luo, W.-Y., Shih, Y.-S., Hung, C.-L., Lo, K. W., Chiang, C.-S., Lo, W.-H., Huang, S.-F., Wang, S.-C., Yu, C., Chien, C.-H., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.129 · Cited by 57
Metadata
- Authors
- Thomas, C. E., Ehrhardt, A., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature Reviews Genetics
- Published
- 2003-05-01
- Volume
- 4
- Issue
- 5
- Pages
- 346-358
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2014356856
- Cited by
- 2,501
- References
- 124
- Citations by year
- 2026: 41 · 2025: 59 · 2024: 110 · 2023: 98 · 2022: 109 · 2021: 116 · 2020: 151 · 2019: 153 · 2018: 150 · 2017: 168 · 2016: 142 · 2015: 143 · 2014: 148 · 2013: 122 · 2012: 109
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- Hospital for Sick Children
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- gene therapy, viral vectors, clinical gene therapy, gene therapy safety, retroviral vectors, clinical trials
- MeSH terms
- Dependovirus, Adenoviridae, Defective Viruses, Genetic Vectors, Humans, Neoplasms, Retroviridae, Viruses, Genetic Therapy, Lentivirus, Simplexvirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.